What a Patient With Refractory Idiopathic Detrusor Overactivity Should Know About Botulinum Neurotoxin Type A Injection

被引:51
|
作者
Khan, Shahid [1 ]
Kessler, Thomas M. [1 ]
Apostolidis, Apostolos [1 ,3 ]
Kalsi, Vinay [1 ]
Panicker, Jalesh [1 ]
Roosen, Alexander [1 ]
Gonzales, Gwen [1 ]
Haslam, Collete [1 ]
Elneil, Sohier
Fowler, Clare J. [1 ]
Dasgupta, Prokar [1 ,2 ]
机构
[1] Univ Coll London Hosp Natl Hlth Serv Fdn Trust, Natl Hosp Neurol & Neurosurg, Dept Uroneurol, London WC1N 3BG, England
[2] Guys & St Thomas Hosp Natl Hlth Serv Fdn Trust, Dept Urol, London, England
[3] Aristotle Univ Thessaloniki, Papageorgiou Hosp, Dept Urol 2, GR-54006 Thessaloniki, Greece
来源
JOURNAL OF UROLOGY | 2009年 / 181卷 / 04期
关键词
urinary bladder; overactive; botulinum toxin type A; recurrence; catheterization; quality of life; TOXIN TYPE-A; QUALITY-OF-LIFE; URINARY-INCONTINENCE; SINGLE-CENTER; DOUBLE-BLIND; ANTICHOLINERGICS; EXPERIENCE; SYMPTOMS; EFFICACY; IMPACT;
D O I
10.1016/j.juro.2008.11.110
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We documented the effects of intradetrusor injections of botulinum neurotoxin type A (Botox (R)) for refractory idiopathic detrusor overactivity so that prospective patients maybe properly informed about possible improvement in quality of life, the duration of interinjection intervals and the risk of clean intermittent self-catheterization. Materials and Methods: A total of 81 consecutive patients with refractory idiopathic detrusor overactivity treated with intradetrusor injections of 200 U botulinum neurotoxin type A at 20 sites per injection course were evaluated in this prospective, nonrandomized, open label cohort study. The primary outcome was changes in quality of life, as assessed by the short form of the Urogenital Distress Inventory and the Incontinence Impact Questionnaire before and after treatment. Secondary outcomes were the interinjection interval and the need for clean intermittent self-catheterization. Results: After intradetrusor botulinum, neurotoxin type A injections there was significant improvement in quality of life, which was sustained after repeat injections. Mean Urogenital Distress Inventory and Incontinence Impact Questionnaire scores decreased from 56 to 26 and 59 to 21 after injection 1 in 81 patients, from 52 to 30 and 51 to 24 after injection 2 in 24, from 40 to 19 and 43 to 17 after injection 3 in 13, from 44 to 17 and 61 to 15 after injection 4 in 6 and from 51 to 17 and 63 to 14 after injection 5 in 4, respectively. The median interinjection interval was 15, 12, 14 and 13 months between injections 1 and 2, 2 and 3, 3 and 4, and 4 and 5, respectively. Considering a post-void residual urine of greater than 100 ml with lower urinary tract symptoms as the indication for clean intermittent self-catheterization, the overall clean intermittent self-catheterization rate after treatment was 43%. Conclusions: Intradetrusor botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity significantly improved quality of life. This effect was sustained after repeat injection. More than 2 of 5 patients with refractory idiopathic detrusor overactivity required clean intermittent self-catheterization after botulinum neurotoxin type A injections and. all prospective patients should be informed about this.
引用
收藏
页码:1773 / 1778
页数:6
相关论文
共 50 条
  • [1] Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity
    Schmid, D. M.
    Roy, S.
    Sulser, T.
    Scheiner, D.
    BJU INTERNATIONAL, 2008, 102 : 7 - 10
  • [2] Intradetrusor injection of botulinum neurotoxin type A (BoNT/A) in the treatment of detrusor overactivity
    Kalsi, V
    Apostolodis, A
    Popat, R
    El-Neil, S
    Fowler, CJ
    Dasgupta, P
    BJU INTERNATIONAL, 2005, 95 : 12 - 12
  • [3] Botulinum neurotoxin type A in neurogenic detrusor overactivity
    Boethig, R.
    Kaufmann, A.
    Bremer, J.
    Pannek, J.
    Domurath, B.
    UROLOGE, 2014, 53 (04): : 524 - 530
  • [4] INTRADETRUSOR INJECTION OF BOTULINUM NEUROTOXIN TYPE A IN PATIENTS WITH IDIOPATHIC DETRUSOR OVERACTIVITY UNDERGOING RADICAL RETROPUBIC PROSTATECTOMY
    Zugor, V.
    Pothl, S.
    Addalil, M.
    Kuehn, R.
    Labanaris, A. P.
    ANTICANCER RESEARCH, 2014, 34 (11) : 6853 - 6853
  • [5] PATIENT SATISFACTION AFTER INTRAVESICAL BOTULINUM TOXIN TYPE A INJECTION FOR REFRACTORY DETRUSOR OVERACTIVITY
    Imam, Hala
    NEUROUROLOGY AND URODYNAMICS, 2011, 30 (02) : 266 - 266
  • [6] SUSTAINED QUALITY OF LIFE IMPROVEMENT AFTER REPEAT INTRADETRUSOR INJECTIONS OF BOTULINUM NEUROTOXIN TYPE A FOR REFRACTORY IDIOPATHIC DETRUSOR OVERACTIVITY
    Kessler, T. M.
    Khan, S.
    Apostolidis, A.
    Kalsi, V
    Panicker, J.
    Roosen, A.
    Elneil, S.
    Fowler, C. J.
    Dasgupta, P.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 137 - 137
  • [7] Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory Idiopathic Detrusor Overactivity Incontinence: Patient-Reported Outcome at 4 Weeks
    Kilinc, Mehmet
    Guven, Selcuk
    EUROPEAN UROLOGY, 2010, 57 (05) : 895 - 896
  • [8] Efficacy and complications of intradetrusor injection with botulinum toxin a in patients with refractory idiopathic detrusor overactivity
    Sahai, Arun
    Dowson, Christopher
    Khan, Mohammad Shamim
    Dasgupta, Prokar
    BJU INTERNATIONAL, 2008, 101 (04) : 515 - 516
  • [9] Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity
    Jeffery, Stephen
    Fynes, Michelle
    Lee, Frank
    Wang, Kate
    Williams, Lin
    Morley, Roland
    BJU INTERNATIONAL, 2007, 100 (06) : 1302 - 1306
  • [10] Intradetrusor injection of botulinum neurotoxin type A (BoNT/A) in the treatment of detrusor overactivity: results of repeat injections
    Kalsi, V.
    Apostolidis, A.
    Popat, R.
    Elneil, S.
    Fowler, C. J.
    Dasgupta, P.
    BJU INTERNATIONAL, 2007, 99 : 26 - 26